Chronic Myeloid Leukemia

Detailed Overview

The BCR::ABL1 fusion gene produces a constitutively active tyrosine kinase that drives the excessive proliferation of myeloid lineage cells while evading apoptosis. CML typically presents in a triphasic clinical course: a protracted chronic phase, which if untreated, inexorably progresses through an accelerated phase to a rapidly fatal blast crisis. The advent of tyrosine kinase inhibitors (TKIs) has transformed CML from a fatal disease to a manageable chronic condition with life expectancy approaching that of the general population.

Epidemiology & Demographics

Incidence is 1-2 cases per 100,000 adults per year. Median age at diagnosis is 64 years. Accounts for 15-20% of all adult leukemias. Slightly more common in men.

Etiological Mechanism

The definitive cause is the t(9;22)(q34;q11.2) translocation, leading to the BCR::ABL1 fusion gene. Exposure to high-dose ionizing radiation (e.g., atomic bomb survivors, nuclear accidents) is the only established risk factor.

Primary Causes

Acquired genetic translocation t(9;22) forming the Philadelphia chromosome

• High-Dose Ionizing Radiation: Exposure significantly increases risk, though most cases are sporadic with no identifiable exposure.

The reciprocal translocation t(9;22) fuses the ABL1 gene from chromosome 9 with the BCR gene on chromosome 22. The resulting BCR::ABL1 fusion protein (most commonly p210) is a constitutively active tyrosine kinase. This kinase permanently activates downstream signaling pathways (RAS, RAF, JUN, MYC, STAT), leading to enhanced proliferation, decreased apoptosis, and altered adhesion of myeloid progenitor cells to the marrow stroma. This results in the premature release of immature myeloid cells into the peripheral blood. Over time, further genetic mutations accumulate, leading to maturation arrest (blast crisis).

Characteristic Clinical Presentation

• Fatigue and Malaise: Due to anemia or hypermetabolic state.
• Left Upper Quadrant Pain/Early Satiety: Caused by massive splenomegaly compressing the stomach.
• Weight Loss: Unexplained weight loss due to hypermetabolism.
• Asymptomatic: Up to 50% of patients are diagnosed incidentally on routine blood work.

Physical Examination Signs

• Splenomegaly (often massive, crossing the midline or reaching the pelvis)
• Hepatomegaly (less common than splenomegaly)
• Sternal tenderness (due to expanding bone marrow)

• Blast Crisis: Transformation into acute leukemia, refractory to most treatments and rapidly fatal without allogeneic stem cell transplant.
• Leukostasis: Hyperviscosity syndrome due to extreme leukocytosis (WBC >300,000/mcL) causing stroke, retinal hemorrhages, or respiratory distress.
• Splenic Infarction: Ischemia of the massively enlarged spleen presenting with acute acute severe LUQ pain.

Diagnostic Criteria & Guidelines

Diagnosis requires the demonstration of the Philadelphia chromosome t(9;22) via conventional cytogenetics (karyotyping) or the BCR::ABL1 fusion gene via FISH or quantitative RT-PCR, in the context of persistent myelocytic leukocytosis.

Differential Diagnosis

• Leukemoid Reaction (due to severe infection, differentiated by high LAP score and absence of Philadelphia chromosome)
• Primary Myelofibrosis
• Essential Thrombocythemia
• Chronic Myelomonocytic Leukemia (CMML)

Laboratory Tests & Biomarkers

• CBC with Differential: Marked leukocytosis (WBC often 100,000 - 500,000/mcL) with a full spectrum of myeloid cells (neutrophils, myelocytes, metamyelocytes). Absolute basophilia and eosinophilia.
• Leukocyte Alkaline Phosphatase (LAP) Score: Markedly decreased (in contrast to elevated in leukemoid reaction).
• Bone Marrow Biopsy: Hypercellular marrow (>90% cellularity) with myeloid hyperplasia and prominent 'dwarf' megakaryocytes.
• Quantitative RT-PCR: Detects and quantifies BCR::ABL1 transcript levels, essential for diagnosis and monitoring molecular response.

Imaging Modalities & Findings

• Abdominal Ultrasound:

• Chronic Phase
  <10% blasts in blood and bone marrow. Asymptomatic or mild symptoms. 85% of diagnoses.
• Accelerated Phase
  10-19% blasts, increasing basophils (≥20%), progressive splenomegaly, or new clonal chromosomal abnormalities.
• Blast Phase (Blast Crisis)
  ≥20% blasts in blood or marrow, or extramedullary blast proliferation. Acts like acute leukemia (AML or ALL).

Second-Line & Adjunctive Therapy

For TKI resistance or intolerance, switch to an alternative 2nd-generation TKI. If the T315I mutation is present, Ponatinib 45 mg PO daily or Asciminib 40 mg PO BID are indicated. Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for TKI-refractory disease or blast phase.

Surgical & Procedural Management

Rarely, splenectomy for massive, painful splenomegaly non-responsive to therapy, though highly uncommon since the TKI era.

Recommended Lifestyle Changes

• Strict adherence to daily oral TKI therapy is critical to prevent resistance and progression.
• Avoid grapefruit juice and St. John's wort, which interfere with CYP3A4 TKI metabolism.
• Cardiovascular risk modification (smoking cessation, lipid control) especially if on Nilotinib or Ponatinib.

Patient Counseling & Advice

Emphasize that CML is treated like a chronic condition and requires lifelong daily medication. Explain that missed doses significantly increase the risk of the leukemia mutating and becoming resistant to the drug (blast crisis). Women of childbearing age must use strict contraception, as TKIs are teratogenic.

Follow-Up & Monitoring Schedule

Strict molecular monitoring using BCR::ABL1 RT-PCR every 3 months. Goal is Major Molecular Response (MMR) (≤0.1% BCR::ABL1 on International Scale) by 12 months. EKG monitoring for QT prolongation if on nilotinib.

Preventive Strategies

No specific primary prevention strategies exist.

Excellent with TKI therapy. The 10-year overall survival rate for patients in chronic phase treated with TKIs is 85-90%, and life expectancy is nearly identical to the age-matched general population.